ITHACA, N.Y. –– Rheonix Inc., developer of automated molecular diagnostic platforms and consumables, added two new members to its management team. Steve Pemberton joins the company as vice president of marketing and sales, and Bryan Greene was named director of consumable manufacturing. These appointments will help Rheonix manufacture, launch, market and distribute its EncompassMDx™ molecular platform and associated Rheonix CARD® assays.
“I am very excited we have brought Steve and Bryan… Read More »
How have automation needs changed in the past few years?
Plank: In molecular testing, the desire among labs for greater efficiencies has increased the demand for automation and workflow advancements. More and more, labs are asking for platforms that offer more menu selection with less testing equipment. So the pattern of consolidation of platforms and menus is the same technological evolution we've seen over the last several years in clinical chemistry… Read More »
ITHACA, N.Y. – Rheonix Inc., developer of automated molecular diagnostic platforms and consumables, has appointed Bill Colston, Ph.D., to its board of directors. Colston, former CEO of QuantaLife Inc., led the development and product launch of Droplet Digital PCR™, a genetic analysis system for quantifying DNA molecules, until his company was acquired by Bio-Rad Laboratories in 2011.
As QuantaLife CEO, Colston raised multiple rounds of private funding and grew the company… Read More »
Ithaca, NY, June 14, 2012 – Rheonix, Inc. today announced that it will present data on its fully automated KRAS CARD™, the newest oncology application of the Company’s powerful molecular diagnostic platform. The KRAS CARD is designed to detect somatic mutations of the KRAS oncogene from either fresh or formaldehyde fixed-paraffin embedded (FFPE) tissue samples automatically on the EncompassMDx™ system. Patients undergoing colorectal cancer therapy are commonly screened, utilizing a… Read More »
Ithaca, NY – December 15, 2011 – Rheonix today announced that it has completed development of a novel microarray production technology to create a high-fidelity microarray, the Hy-Fi Microarray™. HyFi Microarrays provide simple, multiplexed end point detection for molecular assays and, in particular, a novel method to detect single nucleotide polymorphisms (SNPs) on the Rheonix CARD® system. While Rheonix intends to apply this proprietary microarray technology to improve SNP detection,… Read More »
Ithaca, NY – November 16, 2011 – Rheonix today announced the appointment of two individuals—Tom Karpen as Vice President of Operations overseeing engineering, production and quality teams and Terry Howell as Quality Manager. These two new members to the management team will be instrumental as the Company moves toward commercialization of its Rheonix CARD® system, a powerful automated microfluidic platform capable of analyzing raw clinical samples in a variety of… Read More »
Ithaca, NY – July 27, 2011 – Rheonix, Inc. today announced positive results in a new application of its powerful, automated, molecular diagnostic platform, termed SeptiCARD, for the detection of septicemia, the presence of bacteria in the blood often associated with severe infection. Results were presented in a poster session at the American Association for Clinical Chemistry (AACC) Annual Meeting held in Atlanta, Ga., July 24-28, 2011. These data continue… Read More »
Ithaca, NY – July 19, 2011 – Rheonix, Inc. today announced that data demonstrating the powerful, automated molecular diagnostic capabilities of the Rheonix CARD® system will be presented in a poster session at the American Association for Clinical Chemistry (AACC) Annual Meeting being held in Atlanta, GA, July 24-28, 2011. Rheonix will also exhibit at the Clinical Lab Expo, Booth #4434.
“We now have a robust data set supporting our fully… Read More »
ROCHESTER, Minn. — Mayo Clinic today announced that it has reached an agreement with Rheonix, Inc. to collaborate on the performance of a genotyping test for warfarin sensitivity in clinical and research settings. The genotyping test will be available for all patients of Mayo Clinic and is the subject of ongoing research for improved anticoagulation therapy. Additionally, the test will be offered through Mayo Clinic’s reference laboratory, Mayo Medical Laboratories,… Read More »
Ithaca, NY – June 2, 2011 – Rheonix, Inc., developer of the Rheonix CARD® system that provides a powerful microfluidic platform for the evolving molecular diagnostics industry, announced that on June 14, 2011 the U.S. Patent and Trademark Office will issue Patent Number 7,959,875, "Microfluidic Chips and Assay Systems‖ and on April 13, 2011 it allowed Patent Application Number 11/594,444, ―Microfluidic Systems‖ to the Company. These patents, together with existing… Read More »